A Deep Dive into the Trial Results CagriSema, a novel combination therapy comprising cagrilintide and semaglutide, delivered an average weight…
Read More
Biological Pathway Linking Gut Immune Response to Brain-Mediated Appetite Loss Identified by UCSF Researchers
The profound loss of appetite that accompanies severe gastrointestinal distress is a universal human experience, yet the precise biological mechanisms…
Read More
Novo Nordisk’s triple agonist delivers up to 19.7% average weight loss in Phase 2 trial
Novo Nordisk has announced significant positive results from a Phase 2 trial of its experimental triple agonist, UBT251, reporting a…
Read More
UCSF Researchers Identify FTL1 Protein as Primary Driver of Hippocampal Aging and Memory Loss in Landmark Study
The aging process exerts a profound and often debilitating toll on the hippocampus, the specialized region of the brain fundamentally…
Read More
Lilly’s triple agonist achieves 16.8% weight loss in phase 3 trial
Eli Lilly’s investigational drug, retatrutide, a pioneering first-in-class GIP, GLP-1, and glucagon triple hormone receptor agonist, has delivered extraordinary results…
Read More
Brain Immune Response Linked to Early Loss of Smell in Alzheimer’s Disease Patients
The loss of the sense of smell, or anosmia, has long been documented as one of the most frequent and…
Read More
Salk Institute Researchers Identify BCL6 Protein as Critical Factor in Preventing Muscle Loss During Weight Loss and Aging
As the prevalence of glucagon-like peptide-1 (GLP-1) receptor agonists continues to reshape the landscape of metabolic health in the United…
Read More
UCSF Researchers Identify FTL1 Protein as Master Regulator of Hippocampal Aging and Potential Target for Reversing Memory Loss
The human brain is an intricate network of billions of neurons, yet its functional integrity is famously fragile, particularly within…
Read More
Biocytogen and Sihuan Pharmaceutical Forge Strategic Alliance to Accelerate Advanced Therapies, Including Novel Weight Loss Treatments
The pharmaceutical landscape is poised for significant advancement as Biocytogen, a leader in antibody-based drug discovery, and Sihuan Pharmaceutical, a…
Read More
Eli Lilly’s triple agonist achieves 16.8% weight loss in phase 3 trial
Eli Lilly and Company today announced groundbreaking results from a Phase 3 clinical trial, revealing that its investigational triple agonist,…
Read More
